10x Genomics director sells 20,000 TXG shares

10x Genomics, Inc. director John R. Stuelpnagel reported selling a total of 20,000 shares of Class A Common Stock on August 11, 2026.

Rhea-AI Filing Summary

10x Genomics, Inc. director John R. Stuelpnagel reported selling a total of 20,000 shares of Class A Common Stock on August 11, 2026. The sales consisted of 17,000 shares at a weighted average price of $57.5812 per share, executed in multiple trades between $57.50 and $58.1525, and 3,000 shares at $58.7250 per share in a separate transaction.

Insider Trade Summary

Net Seller: 20,000 shares

Net Sell 2 txns

Insider STUELPNAGEL JOHN R

Role Director

Sold 20,000 shs ($1.16M)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock F1	17,000	$57.5812	$979K
Sale	Class A Common Stock	3,000	$58.725	$176K

Holdings After Transaction: Class A Common Stock — 348,436 shares (Direct)

Footnotes (1)

1. F1. This transaction was executed in multiple trades at prices ranging from $57.50 to $58.1525. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Key Figures

Shares sold (first transaction): 17,000 shares Weighted average sale price (first block): $57.5812 per share Price range (first block trades): $57.50 to $58.1525 +3 more

6 metrics

Shares sold (first transaction) 17,000 shares Class A Common Stock sold on August 11, 2026

Weighted average sale price (first block) $57.5812 per share Multiple trades between $57.50 and $58.1525

Price range (first block trades) $57.50 to $58.1525 Range of individual trade prices for 17,000-share sale

Shares sold (second transaction) 3,000 shares Class A Common Stock sold on August 11, 2026

Sale price (second block) $58.7250 per share Single reported price for 3,000-share sale

Total shares sold 20,000 shares Aggregate sellShares in transaction summary

Key Terms

weighted average sale price, open market or private transaction, Rule 10b5-1

3 terms

weighted average sale price financial

"The price reported above reflects the weighted average sale price."

open market or private transaction financial

"Sale in open market or private transaction"

Rule 10b5-1 regulatory

"The filing’s Rule 10b5-1 checkbox is not marked as affirming a trading plan."

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did 10x Genomics (TXG) report in this Form 4?

10x Genomics reported that director John R. Stuelpnagel sold a total of 20,000 shares of Class A Common Stock on August 11, 2026, in two separate open market or private transactions.

How many 10x Genomics (TXG) shares did John R. Stuelpnagel sell and on what date?

John R. Stuelpnagel sold 20,000 TXG shares on August 11, 2026. The transactions comprised 17,000 shares in one set of trades and 3,000 shares in a separate sale on the same date.

At what prices were the TXG shares sold by John R. Stuelpnagel?

The first block of 17,000 TXG shares was sold at a weighted average price of $57.5812 per share, with individual trades between $57.50 and $58.1525. A separate 3,000-share sale was executed at $58.7250 per share.

Were the TXG insider sales executed in multiple trades?

Yes. The sale of 17,000 TXG shares was executed in multiple trades at prices ranging from $57.50 to $58.1525. The reported $57.5812 figure represents the weighted average sale price for those trades.

Does the Form 4 indicate use of a Rule 10b5-1 trading plan for TXG?

No. The filing’s Rule 10b5-1 checkbox is not marked as affirming a trading plan, and the footnotes do not state that these TXG share sales were made pursuant to a pre-arranged trading plan.

What is the total number of TXG shares sold according to the transaction summary?

The transaction summary reports total sellShares of 20,000 for 10x Genomics (TXG). This reflects the combined 17,000-share and 3,000-share sales reported for director John R. Stuelpnagel on August 11, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/13/2026 - 04:13 PM Accepted by SEC EDGAR 08/13/2026 - 04:11 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

STUELPNAGEL JOHN R

(Last) (First) (Middle)

C/O 10X GENOMICS, INC.

6230 STONERIDGE MALL ROAD

(Street)

PLEASANTON CALIFORNIA 94588

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
10x Genomics, Inc. [ TXG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	08/11/2026		S		17,000	D	$57.5812(1)	351,436	D
Class A Common Stock	08/11/2026		S		3,000	D	$58.725	348,436	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $57.50 to $58.1525. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

	/s/ Randy Wu, as Attorney-in-Fact for John R. Stuelpnagel	08/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)